P Valent

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Curr Cancer Drug Targets 11:56-71. 2011
  2. doi request reprint Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Leuk Res 32:1333-7. 2008
  3. doi request reprint The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
    Barbara Peter
    1 Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, A 1090 Vienna, Austria
    J Leukoc Biol 95:95-104. 2014
  4. pmc Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Haematologica 98:1450-7. 2013
  5. pmc Overexpression of primary microRNA 221/222 in acute myeloid leukemia
    Anna Rommer
    Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    BMC Cancer 13:364. 2013
  6. doi request reprint Mast cell activation syndromes: definition and classification
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 68:417-24. 2013
  7. doi request reprint Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications
    Peter Valent
    Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Cancer Res 73:1037-45. 2013
  8. doi request reprint Low blood counts: immune mediated, idiopathic, or myelodysplasia
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
    Hematology Am Soc Hematol Educ Program 2012:485-91. 2012
  9. doi request reprint European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Wien Klin Wochenschr 124:807-14. 2012
  10. doi request reprint Cancer stem cell definitions and terminology: the devil is in the details
    Peter Valent
    the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Nat Rev Cancer 12:767-75. 2012

Collaborators

Detail Information

Publications172 found, 100 shown here

  1. ncbi request reprint Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Curr Cancer Drug Targets 11:56-71. 2011
    ..The current article provides a summary of our knowledge on LSC in various myeloid neoplasms with special reference to novel arising treatment concepts...
  2. doi request reprint Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Leuk Res 32:1333-7. 2008
    ....
  3. doi request reprint The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
    Barbara Peter
    1 Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, A 1090 Vienna, Austria
    J Leukoc Biol 95:95-104. 2014
    ..Whether these drug effects can be translated to application in patients with advanced SM remains to be determined...
  4. pmc Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Haematologica 98:1450-7. 2013
    ..In conclusion, ponatinib exerts major growth-inhibitory effects on neoplastic mast cells in advanced systemic mastocytosis and synergizes with midostaurin and dasatinib in inducing growth arrest in neoplastic mast cells. ..
  5. pmc Overexpression of primary microRNA 221/222 in acute myeloid leukemia
    Anna Rommer
    Department of Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    BMC Cancer 13:364. 2013
    ..In this context, leukemia-associated misexpression of microRNAs (miRNAs) has been studied, but no coherent picture has emerged yet, thus warranting further investigations...
  6. doi request reprint Mast cell activation syndromes: definition and classification
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 68:417-24. 2013
    ..Detailed knowledge about the pathogenesis and complexity of MCAS, and thus establishing the exact final diagnosis, may greatly help in the management and therapy of these patients...
  7. doi request reprint Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications
    Peter Valent
    Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Cancer Res 73:1037-45. 2013
    ..More precise molecular understanding of the different stem cell states thus distinguished should contribute to the development of more effective prognostic and therapeutic tools for cancer diagnosis and treatment...
  8. doi request reprint Low blood counts: immune mediated, idiopathic, or myelodysplasia
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
    Hematology Am Soc Hematol Educ Program 2012:485-91. 2012
    ..This review provides an overview of diagnostic approaches and algorithms for patients with mild unexplained cytopenia(s)...
  9. doi request reprint European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Wien Klin Wochenschr 124:807-14. 2012
    ..These studies will increase our knowledge about optimal management and therapy of patients with mastocytosis in the future...
  10. doi request reprint Cancer stem cell definitions and terminology: the devil is in the details
    Peter Valent
    the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Nat Rev Cancer 12:767-75. 2012
    ....
  11. doi request reprint Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
    Peter Valent
    Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 130:607-612.e9. 2012
    ..The proposed novel criteria, definitions, and terminologies should assist in daily practice, as well as in the preparation and conduct of clinical trials...
  12. doi request reprint Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions
    Peter Valent
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
    Crit Rev Oncol Hematol 82:370-7. 2012
    ..These recommendations should assist in daily practice as well as in the preparation and conduct of clinical trials...
  13. doi request reprint Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Semin Hematol 49:171-81. 2012
    ....
  14. pmc Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
    Peter Valent
    Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Expert Rev Hematol 5:157-76. 2012
    ..In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders...
  15. pmc Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 157:215-25. 2012
    ..Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets...
  16. pmc CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin
    Harald Herrmann
    Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    Haematologica 97:219-26. 2012
    ..CD33 is a well-known stem cell target in acute myeloid leukemia. So far, however, little is known about expression of CD33 on leukemic stem cells in chronic leukemias...
  17. doi request reprint Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells
    Peter Valent
    Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    Best Pract Res Clin Haematol 23:369-78. 2010
    ....
  18. doi request reprint Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
    Peter Valent
    Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Br J Haematol 142:361-78. 2008
    ....
  19. doi request reprint Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Ann Hematol 88:607-11. 2009
    ..The current article represents a meeting report from the latest workshop organized by the group in Vienna in October 2008...
  20. doi request reprint Update on genetic and molecular markers associated with myelodysplastic syndromes
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 50:341-8. 2009
    ..The present article provides a summary of our current knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications...
  21. ncbi request reprint The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells
    H Herrmann
    Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    Curr Cancer Drug Targets 12:51-63. 2012
    ..Together, our data suggest that Hsp32 plays an important role as a survival factor in leukemic stem cells and as a potential new target in AML...
  22. doi request reprint Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions
    P Valent
    Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:548-53. 2009
    ....
  23. doi request reprint Role of interleukins in the regulation of basophil development and secretion
    Peter Valent
    Department of Internal Medicine I, Medical University of Vienna, Austria
    Curr Opin Hematol 17:60-6. 2010
    ..In the current article, most recent discoveries around cytokine regulation of basophils are discussed and compared with previous data...
  24. doi request reprint Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform
    Peter Valent
    Department of Internal Medicine I, Division of Haematology and Hemostaseology, Medical University of Vienna, Austria
    Wien Klin Wochenschr 120:697-709. 2008
    ..The resulting recommendations should assist in diagnosis and prognostication in CML, follow-up and disease-monitoring, patient selection for interventional therapies, and in the preparation and conduct of clinical trials...
  25. doi request reprint Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Res 36:1-5. 2012
    ..In the present review, we discuss current concepts relating to ICUS and IDUS as well as diagnostic approaches and available criteria...
  26. ncbi request reprint On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 34:41-52. 2004
    ..The therapeutic potential of target-specific approaches in malignant mast cell disorders should be evaluated in forthcoming clinical trials in the near future...
  27. doi request reprint Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int Arch Allergy Immunol 156:119-27. 2011
    ..If this is not the case, alternative explanations for symptoms and differential diagnoses have to be considered...
  28. doi request reprint How I treat patients with advanced systemic mastocytosis
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Blood 116:5812-7. 2010
    ..In SM-AHNMD, separate treatment plans should be established for the SM component and the AHNMD component of the disease, with recognition that the AHNMD often has to be managed and treated as a secondary and thus a high-risk neoplasm...
  29. doi request reprint Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 52:740-4. 2011
    ..Finally, CD30 may be considered as a potential target of antibody-based therapeutic intervention in advanced mast cell disorders...
  30. ncbi request reprint Diagnostic evaluation and classification of mastocytosis
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Immunol Allergy Clin North Am 26:515-34. 2006
    ..Important aims for the future are to standardize diagnostic assays and techniques, and to achieve harmonization among centers as a basis for the design of multicenter clinical trials in SM, including the rare ASM and MCL subvariants...
  31. doi request reprint Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Blood Rev 23:157-65. 2009
    ..In a group of patients, oncogenic tyrosine kinases (TK) such as FIP1L1/PDGFRA, can be employed as therapeutic targets by using imatinib or other TK-blocking agents...
  32. ncbi request reprint Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 47:1999-2001. 2006
  33. ncbi request reprint Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Leuk Res 31:727-36. 2007
    ..Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials...
  34. ncbi request reprint Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria
    P Valent
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 37:435-53. 2007
    ..Resulting recommendations and algorithms should greatly facilitate the management of patients with mastocytosis in clinical practice, selection of patients for therapies, and the conduct of clinical trials...
  35. doi request reprint Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
    Peter Valent
    Department of Internal Medicine I, Division of Haematology and Hemostaseology, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Vienna, Austria
    Eur J Clin Invest 40:918-31. 2010
    ..The current review provides an overview on standards in the diagnosis and therapy in CML, with special reference to novel BCR/ABL1 inhibitors...
  36. pmc Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
    P Valent
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:143-9. 2008
    ..These recommendations should facilitate and assist in recognition of iron overload, selection of patients, timing of treatment, drug selection and the measurement of treatment responses...
  37. ncbi request reprint Mastocytosis: pathology, genetics, and current options for therapy
    Peter Valent
    Department of Internal Medicine I, Medical Univeristy of Vienna, Austria
    Leuk Lymphoma 46:35-48. 2005
    ..Examples include the use of STI571 in patients with SM plus hypereosinophilic syndrome (SM-HES) and the FIPL1/PDGFRA fusion gene target, or chemotherapy for eradication of AML in patients with SM-AML...
  38. doi request reprint Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 49:635-8. 2008
    ..Application of these markers may assist in determining the phase of disease and may help to better predict the prognosis in individual patients...
  39. doi request reprint Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
    Leuk Lymphoma 49:604-9. 2008
    ..In this article, possibilities to overcome stem cell resistance in CML by exploiting knowledge on molecular mechanisms that underly the 'stem cell escape' from drug therapy are discussed...
  40. doi request reprint Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review
    Peter Valent
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
    Wien Klin Wochenschr 120:136-51. 2008
    ..Half of these patients may respond to rituximab, although responses usually are short-lived. Sometimes, AIHA that is associated with malignant lymphomas or tumors, disappears after successful anti-lymphoma or anti-tumor therapy...
  41. ncbi request reprint The European Competence Network on Mastocytosis (ECNM)
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
    Wien Klin Wochenschr 116:647-51. 2004
    ..In addition, the ECNM is dedicated to provide the best available information about the disease to patients and physicians...
  42. ncbi request reprint Diagnostic criteria and classification of mastocytosis: a consensus proposal
    P Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Währinger Gürtel 18 20 Vienna, Austria
    Leuk Res 25:603-25. 2001
    ..Criteria proposed in this article should be helpful in this regard...
  43. ncbi request reprint Variable expression of activation-linked surface antigens on human mast cells in health and disease
    P Valent
    Department of Internal Medicine I, University of Vienna, Austria
    Immunol Rev 179:74-81. 2001
    ..The present article gives an overview of MC phenotypes in health and disease, and attempts to provide explanations for the phenotypic variability of MC...
  44. doi request reprint Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells
    M T Krauth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 39:1711-20. 2009
    ..However, these patients suffer not only from MC infiltration and consecutive organ damage but also from MC mediator-related symptoms...
  45. ncbi request reprint Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells
    G H Schernthaner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Blood 98:3784-92. 2001
    ..These data show that neoplastic MCs express functionally active CD2. It is hypothesized that expression of CD2 is associated with pathologic accumulation and function of MCs in systemic mastocytosis...
  46. ncbi request reprint Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells
    W R Sperr
    Department of Internal Medicine I, University of Vienna, Austria
    Int Arch Allergy Immunol 102:170-5. 1993
    ..Furthermore, MCs could be desensitized specifically by pre-incubation of MCs with rhSCF in Ca-free medium. Together, these data suggest that SCF triggers mediator secretion from MCs in various organs via binding to the c-kit receptor...
  47. ncbi request reprint Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells
    M T Krauth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Allergy 61:281-8. 2006
    ..In the present study, we examined the in vitro effects of five different statins on primary human mast cells (MCs), MC progenitors, and the human MC line HMC-1...
  48. doi request reprint Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination
    T Ball
    Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Austria
    Allergy 64:569-80. 2009
    ..Our objective was the construction, purification and immunologic characterization of a genetically modified derivative of the major timothy grass pollen allergen, Phl p 1 for immunotherapy of grass pollen allergy...
  49. doi request reprint Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression
    F Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:447-55. 2008
    ..Basophilic crisis and eosinophilia are well recognized features of advanced chronic myeloid leukaemia. In other myeloid neoplasms, however, transformation with marked basophilia and eosinophilia is considered unusual...
  50. ncbi request reprint Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Leuk Res 25:595-602. 2001
    ..Whether these neoplasms display aberrant gene expression (or gene defects) or represent 'pre-pre-mast cell leukemias', remains unknown...
  51. ncbi request reprint Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , 1090 Vienna, Austria
    Leuk Res 25:529-36. 2001
    ..These data suggest that cytomorphological assessment of bm MC in SM is an important diagnostic approach that may help to delineate between variants of the disease...
  52. ncbi request reprint Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Int J Immunopathol Pharmacol 20:267-78. 2007
    ..Compared to FcepsilonRI-mediated cell activation, IL-3-induced upregulation of CD203c is a late(r) event and is not accompanied by upregulation of CD63...
  53. ncbi request reprint Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes
    W Füreder
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, The University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Eur J Clin Invest 31:894-901. 2001
    ..However, little is known so far about basophil granulocytes in MDS...
  54. ncbi request reprint Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L)
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Hum Pathol 32:545-52. 2001
    ..Apart from these, CD2 may be a novel useful marker because MCs in mastocytosis frequently express this antigen, whereas MCs in other pathologic conditions are CD2 negative...
  55. doi request reprint Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients
    K W Chen
    Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Allergy 67:609-21. 2012
    ..The aim of this study was to develop and characterize an allergy vaccine based on carrier-bound Der p 2 peptides, which should allow reducing IgE- and T-cell-mediated side-effects during specific immunotherapy (SIT)...
  56. ncbi request reprint CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:797-806. 2008
    ..In conclusion, CD203c is a novel activation-linked surface antigen on MC that is upregulated in response to IgE receptor cross-linking and is overexpressed on neoplastic MC in patients with SM...
  57. ncbi request reprint Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell
    H Agis
    Department of Internal Medicine I, University of Vienna, Austria
    J Immunol 151:4221-7. 1993
    ..This is the first definitive demonstration that mast cells are replenished directly from early hemopoietic progenitors and thus form a unique cell lineage within the hemopoietic system...
  58. ncbi request reprint Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)
    H Agis
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence for Clinical and Experimental Oncology CLEXO, Medical University of Vienna, Austria
    Ann Oncol 18:1834-41. 2007
    ..Therefore, monitoring of minimal residual disease (MRD) during treatment with imatinib is important. However, most MRD-parameters are expensive and require special technology. We determined the value of histamine as MRD-marker in CML...
  59. ncbi request reprint A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Leuk Res 25:627-34. 2001
    ..Because of the 'intermediate' clinical signs and absence of progression to aggressive disease, we proposed the term 'smouldering mastocytosis'...
  60. doi request reprint Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry
    C Baumgartner
    Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 38:326-35. 2008
    ..In most cases, the bone marrow is involved. Expression of CD25 in bone marrow MC, with or without coexpression of CD2, is an important minor SM criterion. So far, most studies have examined CD25-expression on MC by flow cytometry...
  61. ncbi request reprint Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Int Arch Allergy Immunol 122:279-86. 2000
    ..Whether such autoantibodies are recurrently produced in patients with Schnitzler's syndrome and play a role in the pathophysiology of the disease remains to be determined...
  62. ncbi request reprint Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients
    K Sonneck
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:11-21. 2008
    ..In aggregate, our data show that recombinant allergens promote expression of CD13 on basophils in sensitized individuals. The functional significance and diagnostic implications of this observation remain to be determined...
  63. ncbi request reprint Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
    M Focke
    Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:1525-33. 2004
    ..Almost 100 million allergic patients are sensitized to the major birch pollen allergen, Bet v 1, a 17 kDa protein containing most of the IgE epitopes present in pollens of trees belonging to the Fagales order and plant-derived food...
  64. ncbi request reprint Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes
    F Wimazal
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , A-1090, Vienna, Austria
    Leuk Res 25:287-94. 2001
    ..The LDH activity should be considered as an important prognostic factor in MDS...
  65. ncbi request reprint A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE
    S Laffer
    Department of Pathophysiology, AKH, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 108:409-16. 2001
    ..CONCLUSION: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells...
  66. ncbi request reprint Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems
    W R Sperr
    Department of Internal Medicine I, University of Vienna, Austria
    Ann Hematol 80:272-7. 2001
    ..Karyotype-based multiparameter systems appear to be particularly effective in defining MDS patients who are at high risk of transforming to leukemia...
  67. ncbi request reprint Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells
    A W Hauswirth
    Department of Medicine I, Medical University of Vienna, Austria
    Eur J Clin Invest 37:73-82. 2007
    ..In the present study, we asked whether leukaemic stem cells in patients with AML express CD33...
  68. ncbi request reprint Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms
    P Samorapoompichit
    Institute of Histology and Embryology, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Blood 98:2580-3. 2001
    ..Therefore, tryptase should not be regarded as specific for mast cells when neoplastic myeloid cells are analyzed...
  69. ncbi request reprint Clinical and biologic diversity of leukemias occurring in patients with mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Leuk Lymphoma 37:473-86. 2000
    ..In the present article, the concomitant occurrence of mastocytosis and leukemia is discussed in the light of the literature and of concepts proposed to explain the biologic basis of this phenomenon...
  70. doi request reprint A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells
    S Laffer
    Division of Immunopathology, Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Allergy 63:695-702. 2008
    ..In this study, we assessed the binding kinetics and affinity of monoclonal antibody 12 (mAb12) for IgE and investigated whether mAb12 can be used for depletion of IgE and isolation of IgE-bearing cells from peripheral blood...
  71. pmc Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7
    H Agis
    Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
    J Clin Pathol 59:396-402. 2006
    ..In chronic myeloid leukaemia (CML), basophilia is a diagnostic and prognostic determinant. So far, however, no reliable approach for routine detection and enumeration of bone marrow basophils has become available...
  72. doi request reprint Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells
    A Bohm
    Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:395-405. 2009
    ..Three mTOR-targeting drugs, rapamycin, everolimus (RAD001) and CCI-779, were applied. The effects of these drugs on growth, survival, apoptosis and VEGF expression in primary AML cells and various AML cell lines were examined...
  73. doi request reprint Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
    L L Remsing Rix
    Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Leukemia 23:477-85. 2009
    ..Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation...
  74. doi request reprint Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    K J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:869-73. 2008
    ..Cladribine (2CdA) and dasatinib are two drugs that counteract the in vitro growth of neoplastic mast cells in SM. However, only little is known about the in vivo effects of these drugs in SM...
  75. doi request reprint Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
    C Sillaber
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 38:43-52. 2008
    ..Recent data suggest that the mammalian target of rapamycin (mTOR) is involved in the regulation of growth of neoplastic cells in chronic myeloid leukaemia (CML)...
  76. doi request reprint Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
    C Sillaber
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:1098-109. 2009
    ..In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable...
  77. ncbi request reprint Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand
    H C Bankl
    Department of Internal Medicine I, University of Vienna, Austria
    Circulation 91:275-83. 1995
    ..The role of redistributed MC and their mediators in the pathophysiology of atrial thrombosis requires further investigation...
  78. ncbi request reprint Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Eur J Clin Invest 33:611-8. 2003
    ..In the present study, we measured the levels of peripheral blood (pb) and bone marrow (bm) CFU in patients with different categories of SM, and compared them with those obtained in MPD patients and healthy controls...
  79. ncbi request reprint Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy
    K V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, A 1090 Vienna, Austria
    Curr Cancer Drug Targets 9:675-89. 2009
    ..Based on these data, it seems desirable to explore the value of Hsp32-targeting drugs as anti-cancer agents in clinical trials...
  80. ncbi request reprint Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells
    Matthias Mayerhofer
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    FASEB J 19:960-2. 2005
    ..In conclusion, rapamycin inhibits growth of CML cells in vitro and in vivo and, in addition, down-regulates expression of VEGF. Both effects may contribute to the antileukemic activity of the drug in CML...
  81. ncbi request reprint Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies
    N Mothes
    Department of Pathophysiology, Vienna General Hospital, University of Vienna, Vienna, Austria
    Clin Exp Allergy 33:1198-208. 2003
    ..The allergen extract-based analyses of immunotherapy-induced effects yielded highly controversial results regarding a beneficial role of therapy-induced IgG antibodies...
  82. ncbi request reprint Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation
    Hermine Agis
    Department of Internal Medicine I, Medical University of Vienna, Austria
    Leuk Lymphoma 45:1453-8. 2004
    ..These data suggest that Imatinib is a useful agent for long term treatment of relapsed CML after allogeneic SCT...
  83. ncbi request reprint Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Haematologica 92:1451-9. 2007
    ..The respective oncoprotein, KIT D816V, exhibits constitutive tyrosine kinase (TK) activity and has been implicated in malignant cell growth. Therefore, several attempts have been made to identify KIT D816V-targeting drugs...
  84. ncbi request reprint Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
    Karl J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, AKH Wien, Waehringer Guertel 18 20, A 1097 Vienna, Austria
    Blood 105:3303-11. 2005
    ..Moreover, the mcl-1 ASO was found to synergize with imatinib in producing growth inhibition in these cells. Together, our data identify MCL-1 as a BCR/ABL-dependent survival factor and interesting target in CML...
  85. ncbi request reprint Expression of cell surface antigens on mast cells: mast cell phenotyping
    Alexander W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Methods Mol Biol 315:77-90. 2006
    ..This chapter gives an overview about the methods of staining of MC in various tissues with special reference to novel diagnostic markers applied in patients with suspected systemic mastocytosis...
  86. ncbi request reprint Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412
    Karl J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Blood 109:3031-41. 2007
    ..1 cells and with PKC412 in HMC-1.2 cells. Together, these data show that MCL-1 is a novel survival factor and an attractive target in neoplastic MCs...
  87. ncbi request reprint Molecular characterization of polygalacturonases as grass pollen-specific marker allergens: expulsion from pollen via submicronic respirable particles
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    J Immunol 172:6490-500. 2004
    ..Our finding that rabbit anti-rPhl p 13 Abs blocked patients' IgE binding to the allergen suggests that rPhl p 13 may be used for immunotherapy of sensitized patients...
  88. ncbi request reprint Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7
    Kerstin Westritschnig
    Department of Pathophysiology, Vienna General Hospital, AKH, Medical University of Vienna, Vienna, Austria
    J Immunol 172:5684-92. 2004
    ....
  89. ncbi request reprint Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy
    Ines Swoboda
    Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Vienna, Austria
    J Immunol 168:4576-84. 2002
    ..01. The latter results suggest that it will be possible to develop strategies for immunotherapy for fish allergy that are based on calcium-free hypoallergenic rCyp c 1.01 derivatives...
  90. ncbi request reprint Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)
    Peter Valent
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 115:515-36. 2003
    ..Recently established scoring systems aimed at predicting survival and evolution of leukemia in MDS may be helpful in this regard...
  91. ncbi request reprint Gastro-duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential
    T Eiwegger
    Department of Pediatrics, Division of General Pediatrics, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 36:1281-8. 2006
    ..We evaluated the effect of in vitro gastro-duodenal digestion of Ara h 1 on T cell reactivity and basophil histamine release...
  92. ncbi request reprint Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib
    Stefan Florian
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Leuk Res 30:1201-5. 2006
    ..Because of the availability of a superior targeted drug (imatinib), it is of importance to screen for FIP1L1/PDGFRalpha in suspected CEL with or without co-existing SM...
  93. doi request reprint Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs
    Karl J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Blood 114:5342-51. 2009
    ..Targeting of Bcl-2 family members by drugs promoting Bim (re)-expression, or by BH3-mimetics such as obatoclax, may be an attractive therapy concept in SM...
  94. ncbi request reprint Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein
    Nadine Mothes-Luksch
    Division of Immunopathology, Department of Pathophysiology, Center of Physiology, Pathophysiology and Immunology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
    J Immunol 181:4864-73. 2008
    ..The mosaic strategy is a general strategy for the reduction of allergenic activity of protein allergens and can be used to convert harmful allergens into safe vaccines...
  95. doi request reprint Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha
    Christian Baumgartner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Exp Hematol 36:1244-53. 2008
    ..However, not all patients with CEL show a response to imatinib. Therefore, several attempts have been made to identify other TK inhibitors that counteract growth of neoplastic eosinophils...
  96. pmc Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536
    Barbara Peter
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Haematologica 96:672-80. 2011
    ..Polo-like kinase-1 is a serine/threonine kinase that plays an essential role in mitosis and has recently been introduced as a new target in myeloid leukemias and solid tumors...
  97. ncbi request reprint Recombinant allergens promote expression of CD203c on basophils in sensitized individuals
    Alexander W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 110:102-9. 2002
    ..During the past few years, several attempts have been made to refine diagnostic assays in clinical allergy by introducing recombinant allergens and novel markers of IgE-dependent cell activation...
  98. ncbi request reprint Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma
    Andreas Chott
    Department of Pathology, University of Vienna, Vienna, Austria
    Am J Surg Pathol 27:1013-9. 2003
    ..Together, neoplastic mast cells in a case of mast cell sarcoma were found to exhibit unique morphologic, phenotypical, and molecular features when compared with mast cells in indolent mastocytosis or normal tissue mast cells...
  99. ncbi request reprint Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    J Allergy Clin Immunol 114:3-11; quiz 12. 2004
    ..The current review provides an overview of mastocytosis and its subvariants and a practical guide that might help to delineate mastocytosis from unrelated systemic disorders...
  100. ncbi request reprint Bone marrow microvessel density and its prognostic significance in AML
    Werner Rabitsch
    Department of Internal Medicine I, Vienna, Austria
    Leuk Lymphoma 45:1369-73. 2004
    ..05). Together, our data suggest that the BM-MVD could be a prognostic parameter concerning survival in patients with AML undergoing allogeneic BMT...
  101. doi request reprint Trimolecular complex formation of IgE, Fc epsilon RI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE
    Christian Lupinek
    Department of Pathophysiology, Division of Immunopathology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    J Immunol 182:4817-29. 2009
    ..In vivo skin testing confirmed the lack of allergenic activity of the ScFv. The recombinant ScFv may represent a universal tool for the IgE-targeted treatment of allergies...